City
Epaper

India to procure over 30 crore COVID-19 vaccine doses per month by January: Sources

By ANI | Updated: October 16, 2021 14:55 IST

India will have a vaccine capacity of 28 crore doses this month, which includes 22 crore Serum Institute of India's Covishield and 6 crore doses of Bharat Biotech Biotech's Covaxin and production of 60 lakh Zydus Cadila's ZyCoV-D doses are also ready, said government sources.

Open in App

India will have a vaccine capacity of 28 crore doses this month, which includes 22 crore Serum Institute of India's Covishield and 6 crore doses of Bharat Biotech Biotech's Covaxin and production of 60 lakh Zydus Cadila's ZyCoV-D doses are also ready, said government sources.

India will have a capacity of more than 30 crores by next year per month, which includes Covishield, Covaxin, ZyCoV-D and Biological E, sources told ANI.

According to the sources, the production of 60 lakh doses of Zydus Cadila's ZyCoV-D are already ready with the company and Biological E will be submitting the data till November end of phase -3 trials. The Biological E is the third Indian company to make Covid-19 vaccines. The company has also started stockpile doses.

Biological E will be providing 30 crore doses and another company that is expected to provide doses is Gennova which is the fourth Indian company doing trials of mRNA vaccines. India is expected to get Gennova's mRNA vaccine doses by February.

Earlier, on September 2, NITI Aayog Member (Health) VK Paul had said that the Hyderabad-based pharmaceutical company, Biological E, is expected to launch its vaccine against coronavirus in October this year.

Paul had toldthat Phase 3 of Biological E's trial is underway. "Stockpile is being produced. We should wait for the results. We hope it'll be in the next month or two. They've made a broad commitment that they'll supply a significant amount by year-end."

India procured more than 26 crore doses in the month of September also.

Centre plans to achieve 100 crore doses in next week.

Earlier, it was expected to reach the target between October 10 to October 12. The delay and decline in Covid vaccination are due to the festival season and hesitation in the second dose.

India may accelerate the export of Covid-19 vaccines under its humanitarian initiative 'Vaccine Maitri' by December after having an excess number of doses in the country.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Bharat BiotechZydus cadila
Open in App

Related Stories

NationalHyderabad: Union Minister Jitendra Singh inaugurates 'One Week One Lab' campaign at CSIR-IICT

NationalOn Republic Day, Bharat Biotech launches first India-made nasal Covid vaccine

NationalUnion Health Minister to launch world's first Made-in-India COVID-19 nasal vaccine tomorrow

NationalBharat Biotech's intranasal heterologous booster dose likely to hit market in February first week

NationalBharat Biotech's intranasal heterologous booster dose likely to hit market in February first week

National Realted Stories

NationalPak troops resort to unprovoked firing on J&K LoC, Indian Army retaliates

NationalNo justification for such acts of terror: Iranian Prez condemns J&K attack in phone call with PM Modi

NationalPoster controversy: Police disperse protestors in Jaipur, say situation under control

NationalGujarat: Vadodara woman duped of Rs 5.61 lakh in visa scam, complaint filed

NationalRetaliatory actions against Pak reflect India’s strong policy against those promoting terror: Raksha Khadse